Precision Medicine

Hint: The finding relied on medical information from more than 46,000 Geisinger patients.

What might this means of data generation teach medicine about drugs?

Cota and Hackensack Meridian Health’s path toward bundled payments holds lessons for others.

Cota's co-founder and Chief Scientific Officer would know: His company just got that amount in Series C.

Harvard University researchers said their findings could help improve wearable robotic devices.

The gene-editing start-up doesn’t demand licensing fees and royalties from academic and commercial researchers.

A genetic variant might be associated with opioid addiction. But it can’t yet predict outcomes for individual patients.

How the early investment could help boost precision cancer therapies.

A team of researchers from Harvard and Brigham and Women's says that their new methodology will be made freely available to other researchers.

The story broke just a day after we published a sweeping feature on Sangamo’s fledgling gene-editing empire.

Sangamo’s ever-evolving zinc finger technology could catapult precision medicine. So why haven’t you heard about it?

Lessons that healthcare can take from the streaming video juggernaut as it tries to personalize care for every patient.

The company's founders say they want to make a world where "cancer is managed just like the common cold” and "100 years old is the new 60.”

"I think we are much closer to real, practical medical applications of the technology."

Andrew Norden, MD, says that he thinks the 2 companies' technologies together are "unsurpassed."

The genomics company said the money will go towards strengthening its intellectual property positions and commercializing 1 of its cancer assays

Traditional guidelines and ICD-10 codes get it wrong, according to the cutting-edge company's chief medical officer.

The Ivy’s bioethics center will collaborate with colleagues at University of Copenhagen to develop frameworks around “black box” medicine.

They are building a research registry of data from 30,000 patients. The goal: help scientists advance sleep medicine.

There simply aren't enough genetic counselors to deliver testing results to every patient.

Technology allows people to screen for hereditary cancers. But what happens afterward?

The pharma company and the precision medicine start-up are chasing better cancer care.

The initiative is similar to the All of Us program being run by the National Institutes of Health in the United States

A new study tackles 3 vexing questions: Do humans have genes that enable regeneration, could they be used to fight cancer, and can AI find them?

Caltech researchers continue to refine the microscopic device, whose potential continues to grow.

The majority of the new funding comes from Chinese genomics giant iCarbonX.

Pharma giant Bristol-Myers Squibb is the newest investor in the genomic testing company.

Why the cutting-edge analytics firm is joining forces with Baptist Health South Florida's year-old cancer center.

"The next wave of biomedical insights is coming from cross-institutional collaborations that produce rapidly increasing amounts of multi-omics data."

Companies face challenges, from courting customers to charming regulators.